login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 




Featured Highlights
1 - 20 of 153   Items
CeloNova gets US FDA approval for clinical trial with Oncozene

CeloNova gets US FDA approval for clinical trial with Oncozene

Friday, 14 Nov 2014
CeloNova BioSciences has announced that the US FDA has granted approval to start an investigational device exemption (IDE) clinical trial for its Oncozene embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of hepatocellular carcinoma. CeloNova gets US FDA approval for clinical trial with Oncozene

Terumo Europe to create an Interventional Oncology division

Tuesday, 04 Nov 2014
Terumo Europe has announced the creation of an Interventional Oncology division that will be active as of 1 April 2015. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states. Terumo Europe to create an Interventional Oncology division
SIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer

SIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer

Tuesday, 30 Sep 2014
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer endorse radioembolisation, specifically with yttrium-90 (Y90) resin microspheres, as a clinically proven technology to “prolong time to liver tumour progression” in patients who have failed to respond to available chemotherapy options. SIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer
Sirtex expands business into Brazil

Sirtex expands business into Brazil

Tuesday, 09 Sep 2014
Sirtex has announced the expansion of its business in Latin America. Sirtex’s SIR-Spheres microspheres are now available to treat inoperable liver tumours in Brazil. Sirtex expands business into Brazil

First patient enrolled in global phase III OPTIMA study of ThermoDox in primary liver cancer

Friday, 05 Sep 2014
Celsion Corporation has announced that the first patient has been enrolled in its pivotal phase III OPTIMA study of ThermoDox in combination with optimised radiofrequency ablation in patients with hepatocellular carcinoma. The first patient was treated at Kyungpook National University Hospital in South Korea. First patient enrolled in global phase III OPTIMA study of ThermoDox in primary liver cancer
DC Bead approved by China Food and Drug Administration

DC Bead approved by China Food and Drug Administration

Tuesday, 02 Sep 2014
BTG and its partner SciClone Pharmaceuticals have announced that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularised tumours. DC Bead approved by China Food and Drug Administration

Study identifies tumour-promoting role of EGFR present in liver macrophages

Monday, 01 Sep 2014
A study group at the Comprehensive Cancer Centre of Medical University of Vienna and AKH Vienna under the guidance of Maria Sibilia from the Institute for Cancer Research has discovered that tumorigenisis of epidermal growth factor receptor (EGFR) does not, as previously assumed, depend on its presence within the tumour cell, but rather from its activity in the cells adjacent to the tumour. Study identifies tumour-promoting role of EGFR present in liver macrophages
The microenvironment of solid tumours matters

The microenvironment of solid tumours matters

Friday, 08 Aug 2014
Despite the rapid growth of imaging and treatment options in interventional oncology, one area that has been poorly understood and overlooked by the interventional community is the role of the tumour microenvironment and its impact on the delivery of therapeutic agents, writes Aravind Arepally. The microenvironment of solid tumours matters

Vascular Solutions launches Gel-Bead bioresorbable embolization spheres

Friday, 01 Aug 2014
Vascular Solutions has announced the US market launch of its Gel-Bead embolization spheres for the treatment of hypervascular tumours. Vascular Solutions launches Gel-Bead bioresorbable embolization spheres
Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment

Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment

Wednesday, 23 Jul 2014
The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star (DFINE) tumour ablation system. Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment
Liver tumour ablation more predictable with Emprint

Liver tumour ablation more predictable with Emprint

Thursday, 17 Jul 2014
Covidien has unveiled an advanced ablation system that offers physicians predictable results regardless of the target location or tissue type. Liver tumour ablation more predictable with Emprint
Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Tuesday, 08 Jul 2014
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or small intestine can result in serious complications, especially gastrointestinal ulcerations, particularly with Y-90 microspheres. Now, temporary antireflux devices are available that appear to provide both adequate retrograde and antegrade protection against nontarget delivery of cytotoxic agents, Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Terumo obtains regulatory approvals for marketing MicroThermX in additional countries

Friday, 27 Jun 2014
BSD Medical Corporation reported that Terumo Europe NV (Terumo) has obtained approvals to market and import the MicroThermX Microwave Ablation System in South Africa, Dubai, Qatar, and Jordan. Terumo obtains regulatory approvals for marketing MicroThermX in additional countries
Three millimetre “ice ball” margin beyond renal tumours adequate for effective cryoablation

Three millimetre “ice ball” margin beyond renal tumours adequate for effective cryoablation

Friday, 13 Jun 2014
The results from a small, animal study challenge previously unsubstantiated published reports claiming that a five to 10mm “ice ball” margin beyond the tumour is necessary for effective cryoablation. Three millimetre “ice ball” margin beyond renal tumours adequate for effective cryoablation

Philips expands interventional oncology portfolio with EmboGuide to see, reach and treat tumour lesions

Friday, 16 May 2014
New live 3D image guidance tool enhances tumour embolization procedures on Philips’ interventional X-ray systems. Philips expands interventional oncology portfolio with EmboGuide to see, reach and treat tumour lesions
Reducing the perils of ablation for thermally sensitive adjacent organs

Reducing the perils of ablation for thermally sensitive adjacent organs

Friday, 16 May 2014
Over the years, we have seen a rapid development of tools, tricks and techniques that enable ablation of tumours located in regions that are in close proximity to thermally sensitive organs or structures, writes Nishita Kothary (Stanford University, USA). Reducing the perils of ablation for thermally sensitive adjacent organs

Surefire system vs. end hole catheter clinical trial eliminates patient variables

Monday, 05 May 2014
Preliminary observations from the trial were presented at the Global Embolization Symposium and Technologies US (GEST US meeting, 1–4 May, San Francisco, USA) and show increased tumour penetration with the Surefire system. Surefire system vs. end hole catheter clinical trial eliminates patient variables
Interventional radiology techniques and results for the management of neuroendocrine liver metastases

Interventional radiology techniques and results for the management of neuroendocrine liver metastases

Wednesday, 30 Apr 2014
Interventional radiology techniques are widely performed and useful in liver metastases from neuroendocrine tumours, but the level of scientific proof is paradoxically low, especially when considering that these techniques are used in patients with cancer, write Maxime Ronot and Valérie Vilgrain Interventional radiology techniques and results for the management of neuroendocrine liver metastases
COSY trial shows highly reduced radioembolization procedure time and radiation dose

COSY trial shows highly reduced radioembolization procedure time and radiation dose

Friday, 28 Mar 2014
Surefire Medical has announced that the COSY clinical trial (Coiling vs. Surefire infusion system in Y90) showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the Surefire Infusion System without coiling. COSY trial shows highly reduced radioembolization procedure time and radiation dose

Sirtex and Guerbet announce collaboration in clinical studies in liver cancer

Thursday, 27 Mar 2014
Sirtex and Guerbet have announced that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. Sirtex and Guerbet announce collaboration in clinical studies in liver cancer
Found: 153   Displaying: 1-20
Results: 1 2 3 4 5 Next Go to:

Related Section


Clinical Trials
Interventional Oncology News
Interventional Oncology Supplement
Key Opinion Leaders discuss the role of Biocompatible's DC Bead at CIRSE and ILCA
IR Views
Literature
Oncology Useful Links

Related Feeds


Most popular


Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

New deep vein thrombosis guidelines: What you need to know
Thursday, 23 Oct 2014
Suresh Vedantham spoke to Interventional News on the latest from the paper “Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus ... New deep vein thrombosis guidelines: What you need to know

Bioresorbable scaffolds can produce comparable acute results to metal stents
Tuesday, 04 Nov 2014
Speaking at the Asian Society for Vascular Surgery meeting (5–7 September, Hong Kong, China), Andrew Holden commented that studies indicate that bioresorbable scaffolds can produce comparable acute ... Bioresorbable scaffolds can produce comparable acute results to metal stents

Features


Stentoplasty: An “exciting frontier” in spinal augmentation
Thursday, 27 Nov 2014
Stentoplasty, or vertebral body stenting, represents the next step in the evolution of cement spinal augmentation where a stent is placed within the vertebral body followed by infusion of cement. Stentoplasty: An “exciting frontier” in spinal augmentation

CO2 angiography should be more widely used
Thursday, 27 Nov 2014
CO2 angiography can decrease both morbidity and mortality for patients, in certain clinical scenarios. For those driven by economics, the cost of 100cc of CO2 is approximately three cents. Its use is ... CO2 angiography should be more widely used

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions